selpercatinib news

All news on selpercatinib (also known as Retevmo): plants, production capacities, investments and involved companies.

31 May 2026

Lilly: Retevmo reduces recurrence/death risk by 83% as adjuvant in early‑stage RET‑fusion NSCLC

Phase 3 LIBRETTO-432 randomized 151 early-stage RET‑fusion NSCLC patients; at 24‑month follow‑up EFS rates 92% vs 61% (treatment vs placebo). Safety: elevated ALT/AST manageable with dose changes.

Who will be producing selpercatinib in the future?

Find out with chemXplore Alpha

Learn more